Skip to main content
. 2013 Oct;4(5):320–334. doi: 10.1177/2040620713490316

Table 3.

Other experimental indications for ECP therapy.

Disease Number of patients Trial and results Study
Systemic sclerosis 64 Multicenter, RCT of ECP versus sham with significant improvement in skin scores compared with baseline for ECP group Knobler et al. [2006]
Solid-organ transplant rejection 61 Phase II RCT in cardiac transplantation of conventional ISP versus ISP + ECP with a significant reduction in acute rejection episodes for ECP group Barr et al. [1998]
Crohn’s disease 28 Multicenter single-arm study of ECP in moderate–severe, refractory Crohn’s with 50% responding according to the Crohn’s disease activity index score Abreu et al. [2009]
Atopic dermatitis 35 Bicenter single-arm study of ECP in severe, refractory patients with 73% responding and a significant overall reduction in atopic dermatitis score Radenhausen et al. [2004]
Type I diabetes 40 RCT of ECP versus sham in newly diagnosed patients with significantly lower insulin requirements for ECP group Ludvigsson et al. [2001]
Pemphigus vulgaris 4 Case series of treatment refractory patients with three of four experiencing complete remission and able to wean other ISP Rook et al. [1989]
Rheumatoid arthritis 7 Open-label pilot study with four apparent responders Malawista et al. [1991]
Systemic lupus erythematosus 10 Open-label pilot study with seven of eight patients completing the trial responding with a significant decrease in clinical activity score Knobler et al. [1992]
Nephrogenic systemic fibrosis 3 Case series with all patients showing clinical response including softening of skin plaques and improved range of movement in all four limbs Mathur et al. [2008]

ECP, extracorporeal photopheresis; ISP, immunosuppression; RCT, randomized controlled trial.